Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oesophageal cancer

Sanofi reception

Sanofi moves to replace Medivation board

Ramps up efforts to seize control of its US biopharma takeover target

Roche Basel Switzerland

Roche gets EU okay for Avastin/Tarceva combination

Lung cancer therapy ‘significantly’ extends progression-free survival

China drug medicine pharma prices

Cancer drugs “less affordable in low-income countries”

China and India are among those hit hardest by the rapidly escalating price of therapies

- PMLiVE

Trial of AbbVie’s Rova-T disappoints at ASCO

But company says the modest trial data is “a good early sign” for lung cancer drug

- PMLiVE

AstraZeneca to develop Lynparza companion diagnostic

Will collaborate with Foundation Medicine on test for its ovarian cancer drug

- PMLiVE

Biosimilar trastuzumab comparable to brand, ASCO hears

Roche’s Herceptin matched in safety and efficacy by Mylan and Biocon’s breast cancer drug

Roche Basel Switzerland

Roche’s Tecentriq works as first-line bladder cancer therapy

New trial data presented at ASCO supports wider use of the drug

Brain cancer glioblastoma

Tension expected as cancer market rises to $150bn-plus

IMS Health report anticipates increased demand for value-based pricing of oncology drugs

Daiichi Sankyo logo

Daiichi pulls study of patritumab in lung cancer

HER3 inhibitor candidate showed no evidence of efficacy in trial analysis

Eli Lilly HQ

Lilly planning 20 new launches by 2023

Will focus on diabetes, immunology, oncology, neurodegeneration and pain

- PMLiVE

An effective commercial model for cancer care

Patient-centric cancer care

Focus on immunotherapies: special magazine from Blue Latitude Health

Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links